Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Ramat Gan, Israel.
Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
Cancer Immunol Res. 2022 Sep 1;10(9):1127-1140. doi: 10.1158/2326-6066.CIR-21-0643.
The effect of tumor/T-cell interactions on subsequent immune infiltration is undefined. Here, we report that preexposure of melanoma cells to cognate T cells enhanced the chemotaxis of new T cells in vitro. The effect was HLA class I-restricted and IFNγ-dependent, as it was abolished by β2M-knockdown, MHC-blocking antibodies, JAK1 inhibitors, JAK1-silencing and IFNgR1-blocking antibodies. RNA sequencing (RNA-seq) of 73 melanoma metastases showed a significant correlation between the interferon-inducible p150 isoform of adenosine-deaminase-acting-on-RNA-1 (ADAR1) enzyme and immune infiltration. Consistent with this, cocultures of cognate melanoma/T-cell pairs led to IFNγ-dependent induction of ADAR1-p150 in the melanoma cells, as visualized in situ using dynamic cell blocks, in ovo using fertilized chick eggs, and in vitro with Western blots. ADAR1 staining and RNA-seq in patient-derived biopsies following immunotherapy showed a rise in ADAR1-p150 expression concurrently with CD8+ cell infiltration and clinical response. Silencing ADAR1-p150 abolished the IFNγ-driven enhanced T-cell migration, confirming its mechanistic role. Silencing and overexpression of the constitutive isoform of ADAR1, ADAR1-p110, decreased and increased T-cell migration, respectively. Chemokine arrays showed that ADAR1 controls the secretion of multiple chemokines from melanoma cells, probably through microRNA-mediated regulation. Chemokine receptor blockade eliminated the IFNγ-driven T-cell chemotaxis. We propose that the constitutive ADAR1 downregulation observed in melanoma contributes to immune exclusion, whereas antigen-specific T cells induce ADAR1-p150 by releasing IFNγ, which can drive T-cell infiltration.
肿瘤/T 细胞相互作用对后续免疫浸润的影响尚未明确。在此,我们报告称,黑色素瘤细胞预先暴露于同源 T 细胞可增强体外新 T 细胞的趋化性。该效应受到 HLA Ⅰ类限制和 IFNγ 依赖性的调控,因为它可被β2M 敲低、MHC 阻断抗体、JAK1 抑制剂、JAK1 沉默和 IFNgR1 阻断抗体所消除。对 73 个黑色素瘤转移灶的 RNA 测序(RNA-seq)显示,干扰素诱导的腺苷脱氨酶作用于 RNA1 的 p150 同工型(ADAR1)酶与免疫浸润之间存在显著相关性。与之一致的是,在体外使用动态细胞块、鸡胚体内使用受精鸡蛋和体外使用 Western blot,我们观察到在共培养的同源黑色素瘤/T 细胞对中,IFNγ 依赖性诱导了黑色素瘤细胞中的 ADAR1-p150。免疫治疗后患者活检的 ADAR1 染色和 RNA-seq 显示 ADAR1-p150 的表达随着 CD8+细胞浸润和临床反应的增加而上升。沉默 ADAR1-p150 可消除 IFNγ 驱动的增强 T 细胞迁移,证实了其在机制上的作用。沉默和过表达 ADAR1 的组成型同工型 ADAR1-p110 分别降低和增加了 T 细胞迁移。趋化因子阵列显示 ADAR1 控制黑色素瘤细胞分泌多种趋化因子,可能通过 microRNA 介导的调控。趋化因子受体阻断消除了 IFNγ 驱动的 T 细胞趋化性。我们提出,在黑色素瘤中观察到的组成型 ADAR1 下调有助于免疫排斥,而抗原特异性 T 细胞通过释放 IFNγ 诱导 ADAR1-p150,这可能驱动 T 细胞浸润。